Chemical Nature and Classification
The active pharmaceutical ingredient is Meglumini acridonacetas. From a pharmacological standpoint, it is classified as a low-molecular-weight interferon (IFN) inducer.
When studying antiviral agents, it is essential to clearly differentiate their mechanisms of action. Note what this drug is not:
- It is not an M2 channel blocker (e.g., amantadine derivatives).
- It is not a neuraminidase inhibitor (e.g., oseltamivir).
- It is not an HIV protease inhibitor.
Its primary pharmacological objective is to prompt the body's own cells to synthesize protective proteins, rather than directly targeting specific viral enzymes alone.
Main Pharmacological Effects
The action of Meglumini acridonacetas is multifaceted. Clinical pharmacology identifies four key effects:
- Antiviral — the primary function aimed at pathogen elimination.
- Immunomodulatory — modulation of the immune response and activation of the cellular arm.
- Anti-inflammatory — limitation of pathological inflammatory reactions in affected tissues.
- Radioprotective — increasing cellular resistance to the damaging effects of ionizing radiation.
Dual Mechanism of Antiviral Action
The drug is unique in combating viral infections through two simultaneous pathways: indirectly (via the immune system) and directly (acting on the virus itself).
1. Indirect Action Mediated by stimulating the production of endogenous (host-derived) interferon. The primary cellular targets include:
- Monocytes (circulating in the blood).
- Macrophages (tissue-resident phagocytes).
- Lymphocytes (cells of adaptive immunity).
2. Direct Action In addition to immune stimulation, the molecule can directly disrupt viral replication within infected cells through three mechanisms:
- Suppression of specific viral protein synthesis.
- Blocking the incorporation of viral nucleic acids (DNA or RNA) into assembling capsids.
- A sharp increase in the proportion of defective viral particles unable to infect new cells.
Pharmacokinetics and Spectrum of Activity
A key pharmacokinetic feature of the drug is its ability to cross the blood-brain barrier (BBB). This property is critical for treating infections affecting the central nervous system.
Its broad antiviral spectrum covers numerous pathogens:
- Respiratory infections: Influenza A and B viruses.
- Herpesviruses: Herpes simplex virus and cytomegalovirus (CMV).
- Hepatotropic viruses: Hepatitis B and C viruses.
- Retroviruses: Human immunodeficiency virus (HIV).
- Neurotropic viruses: Tick-borne encephalitis virus (where BBB penetration is particularly crucial).
- Oncogenic viruses: Human papillomavirus (HPV).